Overview

• WION, citing RT, reports Enteromix showed complete efficacy with no serious side effects and is pending final approval from Russia’s Ministry of Health, with early clinical use said to be underway at oncology centers.
• WION attributes development to the National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology, and describes the shot as a personalized, intramuscular mRNA immunotherapy.
• A separate OpIndia report cites FMBA chief Veronika Skvortsova at the Eastern Economic Forum saying preclinical studies showed strong safety and tumor shrinkage and that Phase I human trials involving up to 48 participants are set to begin after documents were filed with regulators.
• The differing accounts leave the program’s stage unclear, with one outlet describing early clinical use and another describing an imminent first‑in‑human trial.
• Coverage lists intended beneficiaries ranging from lung, breast, colorectal, and pancreatic cancers to chemotherapy‑resistant and high‑risk hereditary cases, and notes a plan to offer the vaccine free to Russian citizens if approved.